Merthyr's heavy anti-PD-1 cancer immunotherapy Keytruda Phase 3 clinical trial reaches major endpoint
-
Last Update: 2020-06-11
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Today, Theof Theof Mercadon (announced that the company's heavy-duty anti-PD-1 cancer immunotherapy Keytruda, as a second-line therapy, reached the primary end of the phase 3 clinicaltrial in patients with advanced metastatic esophageal cancer and gastroesophageal connectivity tumor
sin patients with a CPS score of 10 at the level of tumor PD-L1 expression, Keytruda statistics significantly improved the total survival (OS) of patients compared to chemotherapyKeytruda
Keytruda is a heavy-duty anti-PD-1 therapy developed by Mercado, which activates T lymphocytes to detect and attack tumor cells by blocking the binding of PD-1 to PD-L1 and PD-L2Since its inception, Keytruda has been approved to treat a variety of types of cancer, including melanoma, lung cancer, head and neck cancer, classic Hodgkin's lymphoma and morein a phase 3 clinical trial called KEYNOTE-181, more than 600 patients with esophageal cancer or gastroesophageal connectivity tumors were randomly treated with Keytruda or a physician-selected chemotherapydrug." These patients have received first-line therapy and symptoms continue to worsenThe main endpoint of the trial was OS in all patients and in patients with PD-L1 CPS to 10results showed that Keytruda reached the main endpoint of the trial in patients with PD-L1 CPS s 10In all patients, however, Keytruda failed to meet statistically significant standards, although it improved OS compared to chemotherapy
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
